Get the Stockscreener App
1.08
3.54%
-0.05
Bioaffinity Technologies Inc stock is traded at $1.08, with a volume of 175.46K.
It is down -3.54% in the last 24 hours and down -0.91% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$1.13
Open:
$1.1
24h Volume:
175.46K
Relative Volume:
0.38
Market Cap:
$4.81M
Revenue:
$9.37M
Net Income/Loss:
$-8.45M
P/E Ratio:
-1.3333
EPS:
-0.81
Net Cash Flow:
$-7.27M
1W Performance:
+5.83%
1M Performance:
-0.91%
6M Performance:
-86.54%
1Y Performance:
-91.16%
1-Day Range:
$1.07
$1.14
1-Week Range:
$0.9931
$1.40
52-Week Range:
$0.693
$46.53
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
1.07 | 5.08M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
476.06 | 184.15B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
189.00 | 137.93B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
578.37 | 47.82B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.95 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
288.17 | 29.19B | 3.17B | 642.63M | 516.49M | 10.77 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
Volume Recap: Can bioAffinity Technologies Inc lead its sector in growth2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Study Begins for bioAffinity Technologies’ CyPath Lung Cancer Diagnostic - Medical Product Outsourcing
CyPath Lung Expands Diagnostic Capabilities as bioAffinity Grows Board - StocksToTrade
bioAffinity Launches Major Lung Cancer Detection Study - TipRanks
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic - The Joplin Globe
Aug Ideas: Will bioAffinity Technologies Inc. Equity Warrant stock split attract more investorsJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - Naître et grandir
bioAffinity Announces Upcoming Departure of Two Board Directors - TipRanks
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? - Finviz
bioAffinity Technologies, Inc. (BIAFW) Competitors - Meyka
bioAffinity presents asthma therapy matching research at AAAAI - Investing.com
bioAffinity Showcases Sputum-Based Platform for Personalized Asthma Care - TipRanks
bioAffinity presents asthma therapy matching research at AAAAI By Investing.com - Investing.com Australia
Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study - mx.advfn.com
bioAffinity presents poster showing sputum test can ID receptors for leading asthma biologics - TradingView
bioAffinity Technologies (NASDAQ: BIAF) shows asthma and COPD diagnostic data - Stock Titan
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients - ChartMill
BIAFW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is bioAffinity Technologies Inc. affected by consumer sentimentJuly 2025 Recap & Safe Capital Growth Tips - mfd.ru
Is bioAffinity Technologies Inc stock heavily shorted2025 Geopolitical Influence & Verified Swing Trading Watchlists - baoquankhu1.vn
bioAffinity Technologies, Inc.Common Stock (NQ: BIAF - The Chronicle-Journal
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
bioAffinity launches study to test lung cancer diagnostic By Investing.com - Investing.com Australia
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test - BioSpace
bioAffinity launches study to test lung cancer diagnostic - Investing.com
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample - PharmiWeb.com
bioAffinity Launches New CyPath Lung Validation Study - TipRanks
Bioaffinity announces validation study for lung cancer test - marketscreener.com
New CyPath Lung validation study at BAMC by bioAffinity (BIAF) - Stock Titan
bioAffinity Adjourns Special Stockholder Meeting for Lack Quorum - MSN
bioAffinity Technologies (NASDAQ:BIAF) Stock Price Down 13.8% – Here’s What Happened - Defense World
Buyback Watch: Is bioAffinity Technologies Inc Equity Warrant stock overvalued or fairly pricedNew Guidance & Technical Pattern Based Buy Signals - baoquankhu1.vn
Can bioAffinity Technologies Inc. Equity Warrant weather a recessionTrade Analysis Summary & Reliable Volume Spike Trade Alerts - mfd.ru
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer - BioSpace
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Bur - PharmiWeb.com
bioAffinity Highlights CyPath Lung Case Study in Diagnostics - TipRanks
BioAffinity Technologies, Inc. Releases New Clinical Study Results - marketscreener.com
bioAffinity Highlights CyPath Lung Clinical Utility in Surveillance - TipRanks
Setup Watch: What is bioAffinity Technologies Inc Equity Warrants valuation compared to sectorForecast Cut & Precise Swing Trade Alerts - baoquankhu1.vn
How bioAffinity Technologies Inc. Equity Warrant stock performs in weak economyMarket Sentiment Summary & Risk Controlled Daily Trade Plans - mfd.ru
Is bioAffinity Technologies Inc.’s growth already priced in - mfd.ru
BIAF Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Growth Recap: Will bioAffinity Technologies Inc outperform tech stocksTrade Ideas & Technical Buy Zone Confirmations - baoquankhu1.vn
Will bioAffinity Technologies Inc. benefit from AI trends2025 Investor Takeaways & Low Volatility Stock Suggestions - mfd.ru
Momentum Shift: What is the implied volatility of bioAffinity Technologies IncEntry Point & Intraday High Probability Alerts - baoquankhu1.vn
bioAffinity Technologies Updates Investor Presentation Materials Online - The Globe and Mail
Can bioAffinity Technologies Inc. stock continue upward trendTrade Analysis Report & Accurate Buy Signal Notifications - mfd.ru
bioAffinity Technologies expands medical advisory board with lung experts By Investing.com - Investing.com South Africa
bioAffinity Adds Leading Lung Cancer Experts to Advisory Board - TipRanks
bioAffinity Technologies Appoints New Advisory Board Members - TradingView
bioAffinity Technologies Appoints Three Physicians to Medical and Scientific Advisory Board - citybiz
bioAffinity Technologies expands medical advisory board with lung experts - Investing.com
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):